A Phase 2 interventional study of SB15 PFS in Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO and Diabetic Macular Oedema, sponsored by Samsung Bioepis Co., Ltd.. Completed at 3 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Samsung Bioepis Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 49th largest by enrollment, is one of 4 that started in 2026, is one of 7 in phase 2, and was the 66th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 27
First in 2005; this study’s year is marked. 4 started in 2026.
This study's enrollment of 33 is below the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 66 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 66 have an industry lead sponsor. The 10 most frequent:
Samsung Bioepis Co., Ltd. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Samsung Bioepis Co., Ltd. has 4 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies testing aflibercept in Macular Degeneration, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open label, multicenter, Phase II trial to evaluate the safety and usability of the pre-filled syringe (PFS) of SB15 (Aflibercept biosimilar). Healthcare Professionals (HCPs) followed the Instructions for Use (IFU) to prepare and administer SB15 PFS with intravitreal injection to trial participants with nAMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema (DME).
HCPs will prepare and administer intravitreal injections of SB15 2 mg delivered via PFS to trial participants on Day 1 and safety follow-up will be assessed until Day 7.
Inclusion Criteria: (Key)
Exclusion Criteria: (Key)
Trial participants received a single dose of SB15 PFS containing 2 mg aflibercept in 0.05 mL solution.
Combination Product: SB15 PFS
SB15 provided in a pre-filled syringe (PFS) containing 2 mg aflibercept in 0.05 mL for intravitreal injection
Also known as: aflibercept
Percentage of Successful Task Completions on All of the 12 tasks
A total of 12 tasks were evaluated, and the percentage of HCPs' successful completions on all of the 12 tasks was measured.
Time frame: Day 1
Incidence of ocular adverse events (AEs)
Time frame: Day 1 to Day 7
Percentage of Successful Completion on Each of 12 tasks
Time frame: Day 1
Incidence of AEs and serious adverse events (SAEs)
Time frame: From Day 1 to Day 7
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2026 to primary completion in Sep 2026, 0 months.
Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 0 months is below that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept